Year |
Citation |
Score |
2019 |
Choi KJ, Jang DW, Zomorodi AR, Codd PJ, Friedman A, Abi Hachem R. Novel Application of Steroid Eluting Stent in Petrous Apex Cholesterol Granuloma. Journal of Neurological Surgery. Part B, Skull Base. 80: 500-504. PMID 31534892 DOI: 10.1055/S-0038-1675751 |
0.311 |
|
2019 |
Peters K, Congdon K, Archer G, Woodring S, Jaggers D, Lipp E, Healy P, Herndon J, Soher B, Vlahovic G, Johnson M, Randazzo D, Desjardins A, Friedman H, Friedman A, et al. ATIM-31. SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS Neuro-Oncology. 21: vi8-vi8. DOI: 10.1093/Neuonc/Noz175.030 |
0.318 |
|
2019 |
Gromeier M, Brown M, Beuabier N, Yan H, He Y, Zhang G, Desjardins A, Herndon J, Bolognesi D, Friedman A, Friedman H, McSherry F, Lin X, Wei Z, Nair S, et al. ATIM-27. TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES Neuro-Oncology. 21: vi7-vi7. DOI: 10.1093/Neuonc/Noz175.026 |
0.342 |
|
2019 |
Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Threatt S, Bullock C, Jackman J, Healy P, Lipp E, Sampson J, Friedman A, Friedman H, Ashley D, Bigner D. ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG) Neuro-Oncology. 21: vi6-vi6. DOI: 10.1093/Neuonc/Noz175.023 |
0.329 |
|
2015 |
Weant M, Dunn-Pirio A, Peters K, Vlahovic G, Randazzo D, Herndon J, Healy P, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. Atct-13Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression: A Phase Ii Trial Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov206.13 |
0.346 |
|
2015 |
Agarwal V, Babu R, Manhas A, Perez E, Friedman A, Adamson DC. Factors Affecting Patient Outcomes of Atypical Meningiomas in a Modern Cohort Skull Base Surgery. 76. DOI: 10.1055/S-0035-1546469 |
0.364 |
|
2014 |
Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, et al. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 1517-23. PMID 25361798 DOI: 10.6004/Jnccn.2014.0151 |
0.326 |
|
2014 |
Mowery Y, Wright A, Desjardins A, Peters K, Ranjan T, Vlahovic G, Friedman H, Zomorodi A, Kaylie D, Adogwa O, Nimjee S, Sperduto W, Chagoya G, Fatemi P, McLendon R, ... ... Friedman A, et al. MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS Neuro-Oncology. 16: v130-v131. DOI: 10.1093/Neuonc/Nou260.18 |
0.365 |
|
2014 |
Vlahovic G, Archer G, Lally-Goss D, Reap E, Batich K, Desjardins A, Peters K, Ranjan T, Healy P, Herndon J, Friedman A, Friedman H, Bigner D, Sampson J. IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) Neuro-Oncology. 16: v117-v117. DOI: 10.1093/Neuonc/Nou258.32 |
0.302 |
|
2014 |
Ghiaseddin A, Dunn-Pirio A, Peters K, Vlahovic G, Herndon J, Threatt S, Sampson J, Friedman A, Friedman H, Desjardins A. At-22Phase Ii Trial Of Bevacizumab, Radiation Therapy (Rt) And Temozolomide Followed By Bevacizumab And Temozolomide With Continuation Of Bevacizumab Beyond Progression Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.22 |
0.351 |
|
2014 |
Desjardins A, Sampson J, Peters K, Vlahovic G, Threatt S, Herndon J, Boulton S, Lally-Goss D, McSherry F, Lipp E, Friedman A, Friedman H, Bigner D, Gromeier M. AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM) Neuro-Oncology. 16: v13-v13. DOI: 10.1093/Neuonc/Nou237.21 |
0.344 |
|
2014 |
Desjardins A, Herndon J, McSherry F, Ravelo A, Lipp E, Healy P, Peters K, Vlahovic G, Sampson J, Friedman A, Friedman H. At-20Single Institution Retrospective Review Of Performance Status And Corticosteroid Use In Newly Diagnosed Glioblastoma (Gbm) Patients (Pts) Treated On Bevacizumab (Bev) Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou237.20 |
0.326 |
|
2013 |
Nabors LB, Ammirati M, Bierman PJ, Brem H, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, et al. Central nervous system cancers. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 1114-51. PMID 24029126 DOI: 10.6004/Jnccn.2013.0132 |
0.374 |
|
2011 |
Brem SS, Bierman PJ, Brem H, Butowski N, Chamberlain MC, Chiocca EA, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hesser D, Junck L, Linette GP, Loeffler JS, Maor MH, et al. Central nervous system cancers. Journal of the National Comprehensive Cancer Network : Jnccn. 9: 352-400. PMID 21464144 DOI: 10.6004/Jnccn.2011.0036 |
0.374 |
|
2009 |
Bullitt E, Ewend M, Vredenburgh J, Friedman A, Lin W, Wilber K, Zeng D, Aylward SR, Reardon D. Computerized assessment of vessel morphological changes during treatment of glioblastoma multiforme: report of a case imaged serially by MRA over four years. Neuroimage. 47: T143-51. PMID 19103295 DOI: 10.1016/J.Neuroimage.2008.10.067 |
0.351 |
|
2008 |
Mitchell DA, Xie W, Schmittling R, Learn C, Friedman A, McLendon RE, Sampson JH. Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro-Oncology. 10: 10-8. PMID 17951512 DOI: 10.1215/15228517-2007-035 |
0.322 |
|
2003 |
Gururangan S, McLaughlin C, Quinn J, Rich J, Reardon D, Halperin EC, Herndon J, Fuchs H, George T, Provenzale J, Watral M, McLendon RE, Friedman A, Friedman HS, Kurtzberg J, et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 21: 2187-91. PMID 12775745 DOI: 10.1200/Jco.2003.10.096 |
0.373 |
|
1998 |
Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, ... ... Friedman AH, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3851-7. PMID 9850030 DOI: 10.1200/Jco.1998.16.12.3851 |
0.327 |
|
1998 |
Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, Ashley DM, Rich J, Dolan ME, Pegg AE, Moschel RC, McLendon RE, Kerby T, Herndon JE, Bigner DD, et al. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 3570-5. PMID 9817277 DOI: 10.1200/Jco.1998.16.11.3570 |
0.321 |
|
1996 |
Halperin EC, Herndon J, Schold SC, Brown M, Vick N, Cairncross JG, Macdonald DR, Gaspar L, Fischer B, Dropcho E, Rosenfeld S, Morowitz R, Piepmeier J, Hait W, Byrne T, ... ... Friedman A, et al. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain International Journal of Radiation Oncology Biology Physics. 34: 793-802. PMID 8598355 DOI: 10.1016/0360-3016(95)02025-X |
0.356 |
|
1993 |
Schold S, Zalutsky M, Coleman R, Glantz M, Friedman A, Jaszczak R, Bigner S, Bigner D. Distribution and Dosimetry of I-123-Labeled Monoclonal Antibody 81C6 in Patients with Anaplastic Glioma Investigative Radiology. 28: 488-496. DOI: 10.1097/00004424-199306000-00003 |
0.308 |
|
1981 |
Friedman A, Schauer P, Mertelsmann R, Cirrincione C, Thaler H, Dufour P, Ellis S, Teitelbaum H, Kempin S, Gee T, Arlin Z, Clarkson B. The significance of splenomegaly in 101 adults with acute lymphoblastic leukemia (ALL) at presentation and during remission Blood. 57: 798-801. DOI: 10.1182/Blood.V57.4.798.Bloodjournal574798 |
0.335 |
|
Show low-probability matches. |